Given that STING and HER2 are constitutively expressed at variable levels in multiple tumor cell types,[22, 23] we hypothesized that TZ‐dSA3‐12 could effectively activate STING signaling and enhance tumor cell‐intrinsic innate immunity for tumor control (Figure 4a). The gene discussed is STING1; the disease is neoplasm.